Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling

Fig. 8

RA190 combination with Sorafenib showed synergy against HepG2 cells. a Bar graph depicting HepG2 cell viability after 48 h of each treatment regimen. To seek the conditions of optimal synergy, a checkerboard analysis was performed using titrations of RA190 and Sorafenib. b, c A surface plot of the Synergy score showed the most synergistic cell killing occurred at 0.3 μM RA190 and 0.5 mM Sorafenib

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us